These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 22754953)

  • 1. Alzheimer’s disease: the new promise.
    Strittmatter WJ
    J Clin Invest; 2012 Apr; 122(4):1191. PubMed ID: 22754953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers.
    Bomfim TR; Forny-Germano L; Sathler LB; Brito-Moreira J; Houzel JC; Decker H; Silverman MA; Kazi H; Melo HM; McClean PL; Holscher C; Arnold SE; Talbot K; Klein WL; Munoz DP; Ferreira ST; De Felice FG
    J Clin Invest; 2012 Apr; 122(4):1339-53. PubMed ID: 22476196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline.
    Talbot K; Wang HY; Kazi H; Han LY; Bakshi KP; Stucky A; Fuino RL; Kawaguchi KR; Samoyedny AJ; Wilson RS; Arvanitakis Z; Schneider JA; Wolf BA; Bennett DA; Trojanowski JQ; Arnold SE
    J Clin Invest; 2012 Apr; 122(4):1316-38. PubMed ID: 22476197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exenatide promotes cognitive enhancement and positive brain metabolic changes in PS1-KI mice but has no effects in 3xTg-AD animals.
    Bomba M; Ciavardelli D; Silvestri E; Canzoniero LM; Lattanzio R; Chiappini P; Piantelli M; Di Ilio C; Consoli A; Sensi SL
    Cell Death Dis; 2013 May; 4(5):e612. PubMed ID: 23640454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alzheimer disease: Insulin resistance and AD--extending the translational path.
    Craft S
    Nat Rev Neurol; 2012 Jun; 8(7):360-2. PubMed ID: 22710630
    [No Abstract]   [Full Text] [Related]  

  • 6. Exenatide reduces TNF-α expression and improves hippocampal neuron numbers and memory in streptozotocin treated rats.
    Solmaz V; Çınar BP; Yiğittürk G; Çavuşoğlu T; Taşkıran D; Erbaş O
    Eur J Pharmacol; 2015 Oct; 765():482-7. PubMed ID: 26386291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exenatide exerts cognitive effects by modulating the BDNF-TrkB neurotrophic axis in adult mice.
    Bomba M; Granzotto A; Castelli V; Massetti N; Silvestri E; Canzoniero LMT; Cimini A; Sensi SL
    Neurobiol Aging; 2018 Apr; 64():33-43. PubMed ID: 29331730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amelioration of neurodegenerative changes in cellular and rat models of diabetes-related Alzheimer's disease by exendin-4.
    Chen S; Liu AR; An FM; Yao WB; Gao XD
    Age (Dordr); 2012 Oct; 34(5):1211-24. PubMed ID: 21901364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The diabetes drug liraglutide ameliorates aberrant insulin receptor localisation and signalling in parallel with decreasing both amyloid-β plaque and glial pathology in a mouse model of Alzheimer's disease.
    Long-Smith CM; Manning S; McClean PL; Coakley MF; O'Halloran DJ; Holscher C; O'Neill C
    Neuromolecular Med; 2013 Mar; 15(1):102-14. PubMed ID: 23011726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alzheimer's disease and insulin resistance: translating basic science into clinical applications.
    De Felice FG
    J Clin Invest; 2013 Feb; 123(2):531-9. PubMed ID: 23485579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The role of incretins. Type 2 diabetes with new beginnings].
    MMW Fortschr Med; 2005 Mar; 147(10):48-9. PubMed ID: 15803785
    [No Abstract]   [Full Text] [Related]  

  • 12. TNF-α mediates PKR-dependent memory impairment and brain IRS-1 inhibition induced by Alzheimer's β-amyloid oligomers in mice and monkeys.
    Lourenco MV; Clarke JR; Frozza RL; Bomfim TR; Forny-Germano L; Batista AF; Sathler LB; Brito-Moreira J; Amaral OB; Silva CA; Freitas-Correa L; Espírito-Santo S; Campello-Costa P; Houzel JC; Klein WL; Holscher C; Carvalheira JB; Silva AM; Velloso LA; Munoz DP; Ferreira ST; De Felice FG
    Cell Metab; 2013 Dec; 18(6):831-43. PubMed ID: 24315369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exenatide and pramlintide: new glucose-lowering agents for treating diabetes mellitus.
    Hoogwerf BJ
    Cleve Clin J Med; 2006 May; 73(5):477-84. PubMed ID: 16708716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroprotective role of astaxanthin in hippocampal insulin resistance induced by Aβ peptides in animal model of Alzheimer's disease.
    Rahman SO; Panda BP; Parvez S; Kaundal M; Hussain S; Akhtar M; Najmi AK
    Biomed Pharmacother; 2019 Feb; 110():47-58. PubMed ID: 30463045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diabetes basics. Exenatide and pramlintide. New meds on the block.
    Griffin S; Borders J
    Diabetes Self Manag; 2006; 23(4):74-6, 79. PubMed ID: 16888865
    [No Abstract]   [Full Text] [Related]  

  • 16. Pioglitazone and exenatide enhance cognition and downregulate hippocampal beta amyloid oligomer and microglia expression in insulin-resistant rats.
    Gad ES; Zaitone SA; Moustafa YM
    Can J Physiol Pharmacol; 2016 Aug; 94(8):819-28. PubMed ID: 27389824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Exenatide--an alternative to insulin in the treatment of type 2 diabetes?].
    Kjeldsen R; Sandbaek A
    Ugeskr Laeger; 2008 Sep; 170(39):3039-43. PubMed ID: 18822227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exenatide prevents fat-induced insulin resistance and raises adiponectin expression and plasma levels.
    Li L; Yang G; Li Q; Tan X; Liu H; Tang Y; Boden G
    Diabetes Obes Metab; 2008 Sep; 10(10):921-30. PubMed ID: 18093209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of omeprazole with GLP-1 agonist therapy improves insulin sensitivity and antioxidant activity in liver in type 1 diabetic mice.
    Patel V; Joharapurkar A; Dhanesha N; Kshirsagar S; Detroja J; Patel K; Gandhi T; Patel K; Bahekar R; Jain M
    Pharmacol Rep; 2013; 65(4):927-36. PubMed ID: 24145087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exenatide treatment decreases fasting fibroblast growth factor 21 levels in patients with newly diagnosed type 2 diabetes mellitus.
    Hu Y; Liu J; Zhang H; Xu Y; Hong T; Wang G
    Diabetes Metab; 2016 Nov; 42(5):358-363. PubMed ID: 27178737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.